These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 21605333)

  • 1. Thrombin generation assay using factor IXa as a trigger to quantify accurately factor VIII levels in haemophilia A.
    Ninivaggi M; Dargaud Y; van Oerle R; de Laat B; Hemker HC; Lindhout T
    J Thromb Haemost; 2011 Aug; 9(8):1549-55. PubMed ID: 21605333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mild phenotype in severe hemophilia A with Arg1781His mutation is associated with enhanced binding affinity of factor VIII for factor X.
    Yada K; Nogami K; Wakabayashi H; Fay PJ; Shima M
    Thromb Haemost; 2013 Jun; 109(6):1007-15. PubMed ID: 23467620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A modified thrombin generation test for investigating very low levels of factor VIII activity in hemophilia A.
    Matsumoto T; Nogami K; Ogiwara K; Shima M
    Int J Hematol; 2009 Dec; 90(5):576-582. PubMed ID: 19937483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombin generation in haemophilia A patients with mutations causing factor VIII assay discrepancy.
    Gilmore R; Harmon S; Gannon C; Byrne M; O'Donnell JS; Jenkins PV
    Haemophilia; 2010 Jul; 16(4):671-4. PubMed ID: 20148980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clot waveform analysis using CS-2000i™ distinguishes between very low and absent levels of factor VIII activity in patients with severe haemophilia A.
    Matsumoto T; Nogami K; Tabuchi Y; Yada K; Ogiwara K; Kurono H; Arai N; Shima M
    Haemophilia; 2017 Sep; 23(5):e427-e435. PubMed ID: 28750470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X.
    Ogiwara K; Nogami K; Matsumoto N; Noguchi-Sasaki M; Hirata M; Soeda T; Shima M
    Int J Hematol; 2020 Nov; 112(5):621-630. PubMed ID: 32748217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A modified thrombin generation test for the measurement of factor VIII concentrates.
    McIntosh JH; Owens D; Lee CA; Raut S; Barrowcliffe TW
    J Thromb Haemost; 2003 May; 1(5):1005-11. PubMed ID: 12871369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mild hemophilia A with factor VIII assay discrepancy: using thrombin generation assay to assess the bleeding phenotype.
    Trossaërt M; Regnault V; Sigaud M; Boisseau P; Fressinaud E; Lecompte T
    J Thromb Haemost; 2008 Mar; 6(3):486-93. PubMed ID: 18047548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII:C).
    Shima M; Matsumoto T; Fukuda K; Kubota Y; Tanaka I; Nishiya K; Giles AR; Yoshioka A
    Thromb Haemost; 2002 Mar; 87(3):436-41. PubMed ID: 11916076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring rFVIII prophylaxis dosing using global haemostasis assays.
    Al Hawaj MA; Martin EJ; Venitz J; Barrett JC; Kuhn JG; Nolte ME; Brophy DF
    Haemophilia; 2013 May; 19(3):409-14. PubMed ID: 23510278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies.
    Nogami K; Soeda T; Matsumoto T; Kawabe Y; Kitazawa T; Shima M
    J Thromb Haemost; 2018 Jul; 16(7):1383-1390. PubMed ID: 29734520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII-equivalence.
    Leksa NC; Aleman MM; Goodman AG; Rabinovich D; Peters R; Salas J
    J Thromb Haemost; 2019 Jul; 17(7):1044-1052. PubMed ID: 30887655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the thrombin generation profiles of four different rFVIII products in FVIII-deficient plasma using FIXa and FXIa activation.
    Brophy DF; Martin EJ; Ninivaggi M; Mohammed BM; Barrett JC; Kuhn J; Nolte ME; Waters EK; Ezban M
    Haemophilia; 2018 Sep; 24(5):815-822. PubMed ID: 30112856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of the thrombin generation test components to measure potency of factor VIII concentrates.
    Jha NK; Shestopal SA; Gourley MJ; Woodle SA; Liang Y; Sarafanov AG; Weinstein M; Ovanesov MV
    Haemophilia; 2016 Sep; 22(5):780-9. PubMed ID: 27038076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay.
    Matsumoto T; Shima M; Takeyama M; Yoshida K; Tanaka I; Sakurai Y; Giles AR; Yoshioka A
    J Thromb Haemost; 2006 Feb; 4(2):377-84. PubMed ID: 16420569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyr346-->Cys mutation results in factor VIII:C assay discrepancy and a normal bleeding phenotype - is this mild haemophilia A?
    Lyall H; Hill M; Westby J; Grimley C; Dolan G
    Haemophilia; 2008 Jan; 14(1):78-80. PubMed ID: 18034822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppressing protein Z-dependent inhibition of factor Xa improves coagulation in hemophilia A.
    Girard TJ; Lasky NM; Grunz K; Broze GJ
    J Thromb Haemost; 2019 Jan; 17(1):149-156. PubMed ID: 30451376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison between coagulation factor VIII quantified with one-stage activity assay and with mass spectrometry in haemophilia A patients: Proof of principle.
    Donners AAMT; van Maarseveen EM; Weetink YRJ; El Amrani M; Fischer K; Rademaker CMA; Egberts TCG; Huisman A; Musson REA
    Int J Lab Hematol; 2020 Dec; 42(6):819-826. PubMed ID: 32633067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged α-thrombin-related activation and delayed active protein C-associated degradation confer mild phenotype in a patient with severe hemophilia A with F8 p.H118R.
    Miyashita R; Shinozawa K; Inaba H; Amano K; Kinai E
    Int J Hematol; 2022 Oct; 116(4):489-499. PubMed ID: 35590009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical utility of activated partial thromboplastin time clot waveform analysis and thrombin generation test in the evaluation of bleeding phenotype in Hemophilia A.
    Dave RG; Geevar T; Mammen JJ; Vijayan R; Mahasampath G; Nair SC
    Indian J Pathol Microbiol; 2021; 64(1):117-122. PubMed ID: 33433420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.